Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 2 | 1 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- Cantor Fitzgerald
- Alliance Global Partners
- SVB Leerink
- HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Abeona Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 08/24/2023 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | 755.39% | Cantor Fitzgerald | Kristen Kluska | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 07/13/2023 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | 755.39% | Cantor Fitzgerald | Kristen Kluska | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 05/24/2023 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | 350.21% | Alliance Global Partners | James Molloy | → $20 | Reiterates | → Buy | Get Alert |
| 11/14/2022 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | 35.06% | SVB Leerink | Mani Foroohar | $5 → $6 | Maintains | Market Perform | Get Alert |
| 11/08/2022 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | 800.41% | Cantor Fitzgerald | Kristen Kluska | $22 → $40 | Maintains | Overweight | Get Alert |
| 08/11/2022 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | 12.55% | SVB Leerink | Mani Foroohar | $1 → $5 | Maintains | Market Perform | Get Alert |
| 11/30/2021 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | -77.49% | SVB Leerink | Mani Foroohar | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/29/2021 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | -9.96% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 07/19/2021 | ABEO | Buy Now | Abeona Therapeutics | $4.44 | 12.55% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
What is the target price for Abeona Therapeutics (ABEO)?
The latest price target for Abeona Therapeutics (NASDAQ: ABEO) was reported by Cantor Fitzgerald on August 24, 2023. The analyst firm set a price target for $38.00 expecting ABEO to rise to within 12 months (a possible 755.39% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Abeona Therapeutics (ABEO)?
The latest analyst rating for Abeona Therapeutics (NASDAQ: ABEO) was provided by Cantor Fitzgerald, and Abeona Therapeutics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Abeona Therapeutics (ABEO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abeona Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abeona Therapeutics was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.
Is the Analyst Rating Abeona Therapeutics (ABEO) correct?
While ratings are subjective and will change, the latest Abeona Therapeutics (ABEO) rating was a reiterated with a price target of $0.00 to $38.00. The current price Abeona Therapeutics (ABEO) is trading at is $4.44, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.